Dishman Carbogen Amcis Limited has announced that its subsidiary, CARBOGEN AMCIS AG, has formed a strategic partnership with Celonic Group to develop a fully integrated Antibody-Drug Conjugate (ADC) platform. This collaboration aims to provide a comprehensive solution for ADC development and manufacturing, addressing a critical need in the biopharmaceutical sector.

Key Highlights of the Partnership

• Integrated Expertise: The alliance combines Celonic's advanced biologics capabilities with CARBOGEN AMCIS's expertise in payload synthesis, conjugation, and sterile fill-finish.
• Streamlined Process: The partnership aims to create a seamless, end-to-end platform for ADC innovators, potentially speeding up timelines and simplifying the supply chain.
• Comprehensive Services: The integrated offering includes cell line development, antibody production, payload and linker synthesis, ADC conjugation, and sterile fill-finish.

Strategic Implications

The collaboration between CARBOGEN AMCIS and Celonic Group is positioned to meet the rising demand for ADCs, particularly in targeted cancer treatments. By offering a single, coordinated platform from cell line to commercial fill-finish, the partnership aims to accelerate innovation and reduce complexity for their partners in the biopharmaceutical industry.

Executive Insights

Stephan Fritschi, CEO of Carbogen Amcis Group, stated, "The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility."

Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group, added, "For more than 2 decades now we've been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies, precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end-to-end ADC path—from cell line to commercial fill-finish—under one coordinated platform."

Future Developments

CARBOGEN AMCIS is exploring capacity expansion, including the potential implementation of continuous-flow conjugation using custom micro-equipment skids. This innovation could further enhance the precision and efficiency of ADC production.

The strategic alliance between Dishman Carbogen Amcis's subsidiary and Celonic Group represents a significant development in the ADC space, potentially offering biopharmaceutical companies a more streamlined and efficient path from development to commercialization of these complex therapies.

Dishman Carbogen Amcis Limited (DCAL), a prominent player in the pharmaceutical industry, has successfully increased its authorized share capital, as approved by shareholders through a special resolution passed via postal ballot on September 19, 2025.

Key Highlights of the Capital Increase

• Increase Amount: The company has raised its authorized share capital by Rs. 3.95 crores.
• New Shares Created: An additional 1,97,50,000 equity shares of Rs. 2 each were created.
• Total Authorized Capital: The move has elevated the total authorized share capital from Rs. 34.05 crores to Rs. 38.00 crores.
• Total Equity Shares: The number of equity shares has increased from 17,02,50,000 to 19,00,00,000.

Shareholder Approval Process

The special resolution for altering the Capital Clause of the Memorandum of Association (MoA) was passed through a postal ballot. The e-voting period commenced on August 21, 2025, at 9:00 AM (IST) and concluded on September 19, 2025, at 5:00 PM (IST). The results were confirmed through a scrutinizer's report dated September 19, 2025.

Additional Resolutions Passed

Along with the capital increase, shareholders also approved several other significant resolutions:

1. Raising funds through the issue of equity shares or other eligible securities.
2. Re-appointment of Mrs. Deohooti J. Vyas as a Whole-time Director.
3. Confirmation of Mr. Dhaval Rameshchandra Shah's appointment as a Non-Executive and Non-Independent Director.

Implications for Dishman Carbogen Amcis

This increase in authorized share capital provides Dishman Carbogen Amcis with enhanced financial flexibility. It potentially allows the company to issue new shares for various corporate purposes, which may include raising additional capital, funding expansion plans, or other strategic initiatives.

The company's move to increase its authorized capital, coupled with the approval for raising funds through various methods, suggests that Dishman Carbogen Amcis might be preparing for future growth or investment opportunities.